HIMS
The diet-drug party got a surprise chaperone
Hims & Hers was having a very good run in the GLP-1 weight-loss sandbox, and then the FDA showed up like the hall monitor nobody invited. The company fell after regulators cracked down on unapproved weight-loss drugs, which is investor-speak for: the easy money just got harder.
Why you should care
This isn't just bureaucratic paperwork collecting dust in a drawer. Hims has leaned into compounded and unapproved versions of buzzy weight-loss treatments, and that business has been a shiny growth story. When the FDA turns up the heat, it can mean:
- more restrictions on what Hims can sell,
- more legal and compliance headaches,
- and potentially less growth from one of its buzziest categories.
The awkward part
For a telehealth company that wants to look like the cool, modern healthcare platform, getting dragged into a regulatory scrum is not exactly ideal. Investors love growth until the regulators ask to see the homework.
Big picture: if Hims wants to keep the weight-loss engine humming, it may need to prove the business can survive without skating too close to the edge of the rulebook.